\documentclass[twocolumn,twoside]{article}
\makeatletter\if@twocolumn\PassOptionsToPackage{switch}{lineno}\else\fi\makeatother

\usepackage{amsfonts,amssymb,amsbsy,latexsym,amsmath,tabulary,graphicx,times,xcolor}

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
% Following additional macros are required to function some 
% functions which are not available in the class used.
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
\usepackage{url,multirow,morefloats,floatflt,cancel,tfrupee}
\makeatletter


\AtBeginDocument{\@ifpackageloaded{textcomp}{}{\usepackage{textcomp}}}
\makeatother
\usepackage{colortbl}
\usepackage{xcolor}
\usepackage{pifont}
\usepackage[nointegrals]{wasysym}
\urlstyle{rm}
\makeatletter

%%%For Table column width calculation.
\def\mcWidth#1{\csname TY@F#1\endcsname+\tabcolsep}

%%Hacking center and right align for table
\def\cAlignHack{\rightskip\@flushglue\leftskip\@flushglue\parindent\z@\parfillskip\z@skip}
\def\rAlignHack{\rightskip\z@skip\leftskip\@flushglue \parindent\z@\parfillskip\z@skip}

%Etal definition in references
\@ifundefined{etal}{\def\etal{\textit{et~al}}}{}


%\if@twocolumn\usepackage{dblfloatfix}\fi
\usepackage{ifxetex}
\ifxetex\else\if@twocolumn\@ifpackageloaded{stfloats}{}{\usepackage{dblfloatfix}}\fi\fi

\AtBeginDocument{
\expandafter\ifx\csname eqalign\endcsname\relax
\def\eqalign#1{\null\vcenter{\def\\{\cr}\openup\jot\m@th
  \ialign{\strut$\displaystyle{##}$\hfil&$\displaystyle{{}##}$\hfil
      \crcr#1\crcr}}\,}
\fi
}

%For fixing hardfail when unicode letters appear inside table with endfloat
\AtBeginDocument{%
  \@ifpackageloaded{endfloat}%
   {\renewcommand\efloat@iwrite[1]{\immediate\expandafter\protected@write\csname efloat@post#1\endcsname{}}}{\newif\ifefloat@tables}%
}%

\def\BreakURLText#1{\@tfor\brk@tempa:=#1\do{\brk@tempa\hskip0pt}}
\let\lt=<
\let\gt=>
\def\processVert{\ifmmode|\else\textbar\fi}
\let\processvert\processVert

\@ifundefined{subparagraph}{
\def\subparagraph{\@startsection{paragraph}{5}{2\parindent}{0ex plus 0.1ex minus 0.1ex}%
{0ex}{\normalfont\small\itshape}}%
}{}

% These are now gobbled, so won't appear in the PDF.
\newcommand\role[1]{\unskip}
\newcommand\aucollab[1]{\unskip}
  
\@ifundefined{tsGraphicsScaleX}{\gdef\tsGraphicsScaleX{1}}{}
\@ifundefined{tsGraphicsScaleY}{\gdef\tsGraphicsScaleY{.9}}{}
% To automatically resize figures to fit inside the text area
\def\checkGraphicsWidth{\ifdim\Gin@nat@width>\linewidth
	\tsGraphicsScaleX\linewidth\else\Gin@nat@width\fi}

\def\checkGraphicsHeight{\ifdim\Gin@nat@height>.9\textheight
	\tsGraphicsScaleY\textheight\else\Gin@nat@height\fi}

\def\fixFloatSize#1{}%\@ifundefined{processdelayedfloats}{\setbox0=\hbox{\includegraphics{#1}}\ifnum\wd0<\columnwidth\relax\renewenvironment{figure*}{\begin{figure}}{\end{figure}}\fi}{}}
\let\ts@includegraphics\includegraphics

\def\inlinegraphic[#1]#2{{\edef\@tempa{#1}\edef\baseline@shift{\ifx\@tempa\@empty0\else#1\fi}\edef\tempZ{\the\numexpr(\numexpr(\baseline@shift*\f@size/100))}\protect\raisebox{\tempZ pt}{\ts@includegraphics{#2}}}}

%\renewcommand{\includegraphics}[1]{\ts@includegraphics[width=\checkGraphicsWidth]{#1}}
\AtBeginDocument{\def\includegraphics{\@ifnextchar[{\ts@includegraphics}{\ts@includegraphics[width=\checkGraphicsWidth,height=\checkGraphicsHeight,keepaspectratio]}}}

\DeclareMathAlphabet{\mathpzc}{OT1}{pzc}{m}{it}

\def\URL#1#2{\@ifundefined{href}{#2}{\href{#1}{#2}}}

%%For url break
\def\UrlOrds{\do\*\do\-\do\~\do\'\do\"\do\-}%
\g@addto@macro{\UrlBreaks}{\UrlOrds}



\edef\fntEncoding{\f@encoding}
\def\EUoneEnc{EU1}
\makeatother
\def\floatpagefraction{0.8} 
\def\dblfloatpagefraction{0.8}
\def\style#1#2{#2}
\def\xxxguillemotleft{\fontencoding{T1}\selectfont\guillemotleft}
\def\xxxguillemotright{\fontencoding{T1}\selectfont\guillemotright}

\newif\ifmultipleabstract\multipleabstractfalse%
\newenvironment{typesetAbstractGroup}{}{}%

%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%

\usepackage[authoryear]{natbib}



\newif\ifnokeywords\nokeywordsfalse

\makeatletter\input{size10-pointfive.clo}\makeatother%
\definecolor{kwdboxcolor}{RGB}{242,242,242}
\usepackage[hidelinks,colorlinks=true,allcolors=blue]{hyperref}
\linespread{1}                 
\def\floatpagefraction{0.8}

\usepackage[paperheight=11.69in,paperwidth=8.26in,top=1in,bottom=1in,left=1in,right=.75in,headsep=24pt]{geometry}

\usepackage{multirow-custom}

\makeatletter

\def\hlinewd#1{%
  \noalign{\ifnum0=`}\fi\hrule \@height #1%
  \futurelet\reserved@a\@xhline}
\def\tbltoprule{\hlinewd{1pt}\\[-14pt]}
\def\tblbottomrule{\noalign{\vspace*{6pt}}\hline\noalign{\vspace*{2pt}}}
\def\tblmidrule{\hline\noalign{\vspace*{2pt}}}



\let\@articleType\@empty
\let\@journalDoi\@empty
\let\@journalVolume\@empty
\let\@journalIssue\@empty
\let\@crossMarkLink\@empty
\let\@receivedDate\@empty
\let\@acceptedDate\@empty
\let\@revisedDate\@empty
\let\@publishedDate\@empty
\let\@copyrightYear\@empty
\let\@firstPage\@empty
\def\articleType#1{\gdef\@articleType{#1}}
\def\journalDoi#1{\gdef\@journalDoi{#1}}
\def\crossMarkLink#1{\gdef\@crossMarkLink{#1}}
\def\receivedDate#1{\gdef\@receivedDate{#1}}
\def\acceptedDate#1{\gdef\@acceptedDate{#1}}
\def\revisedDate#1{\gdef\@revisedDate{#1}}
\def\publishedDate#1{\gdef\@publishedDate{#1}}
\def\copyrightYear#1{\gdef\@copyrightYear{#1}}
\def\journalVolume#1{\gdef\@journalVolume{#1}}
\def\journalIssue#1{\gdef\@journalIssue{#1}}
\def\firstPage#1{\gdef\@firstPage{#1}}
\let\@issuelogo\@empty%
\let\@issuelogoex\@empty%
\def\issuelogo#1{\gdef\@issuelogo{#1}}
\def\issuelogoex#1{\gdef\@issuelogoex{#1}}


\def\author#1{%
  \gdef\@author{%
    \hskip-\dimexpr(\tabcolsep)\hskip5pt%
    \parbox{\dimexpr\textwidth-1pt}%
    {\fontsize{11}{13}\selectfont\raggedright #1}%
  }%
}


\usepackage{pharmascope-abs}
\usepackage{caption}
\usepackage{lastpage}
\usepackage{fancyhdr}
\usepackage[noindentafter,explicit]{titlesec}
\usepackage{fontspec}

\setmainfont[%
BoldFont=cambriab.ttf,%
ItalicFont=CAMBRIAI.TTF,%
BoldItalicFont=CAMBRIAZ.TTF]{Cambria.ttf}
\lefthyphenmin = 3

\def\title#1{%
  \gdef\@title{%
      \vspace*{-40pt}%
       \ifx\@articleType\@empty\else{\fontsize{10}{12}\scshape\selectfont\hspace{8pt}\@articleType\hfill\mbox{}\par\vspace{2pt}}\fi%
       \minipage{\linewidth}
         \hrulefill\\[-0.7pt]%%{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}\hfill
         \mbox{~}\hspace{5pt}\parbox{.1\linewidth}{\IfFileExists{images/\@issuelogo.\@issuelogoex}{\includegraphics[width=79pt,height=61pt]{images/\@issuelogo.\@issuelogoex}}{\includegraphics[width=75pt,height=50pt]{ijrps_logo.png}}}\hfill
         \fcolorbox{kwdboxcolor}{kwdboxcolor}{\parbox{.792\linewidth}{%
          \begin{center}\fontsize{17}{17}\selectfont\scshape\vskip-7pt International Journal of Research in Pharmaceutical Sciences\hfill\end{center}%
          \vspace*{-10pt}\hspace*{4pt}{\fontsize{8}{9}\selectfont Published by JK Welfare \& Pharmascope Foundation\hfill  Journal Home Page: \href{www.ijrps.com}{\color{blue}\underline{\smash{www.ijrps.com}}}}\hspace*{4pt}\mbox{}}}%
       \par\vspace*{-1pt}\rule{\linewidth}{1.3pt}%
       \endminipage%
    \par\vspace*{9.2pt}\parbox{.98\linewidth}{\linespread{.9}\raggedright\fontsize{14}{17}\selectfont #1}%
    \vspace*{-8pt}%
  }
}


\setlength{\parindent}{0pt}
\setlength{\parskip}{0.4pc plus 1pt minus 1pt}

\def\abbrvJournalTitle{Int. J. Res. Pharm. Sci.}

\fancypagestyle{headings}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
}\pagestyle{headings}

                                                         
\fancypagestyle{plain}{%
  \renewcommand{\headrulewidth}{0pt}%
  \renewcommand{\footrulewidth}{0.3pt}%
  \fancyhf{}%
  \fancyhead[R]{%
    \fontsize{9.12}{11}\selectfont\RunningAuthor,\ \abbrvJournalTitle,\ \ifx\@journalVolume\@empty X\else\@journalVolume\fi%
    \ifx\@journalIssue\@empty\else(\@journalIssue)\fi%
    ,\ \ifx\@firstPage\@empty 1\else\@firstPage\fi-\pageref*{LastPage}%
  }%
  \fancyfoot[LO,RE]{\fontsize{9.12}{11}\selectfont\textcopyright\ International Journal of Research in Pharmaceutical Sciences}%
  \fancyfoot[RO,LE]{\fontsize{9.12}{11}\selectfont\thepage}
  \ifx\@firstPage\@empty\else\setcounter{page}{\@firstPage}\fi
}


\def\NormalBaseline{\def\baselinestretch{1.1}}
\usepackage{textcase}
\setcounter{secnumdepth}{0}

\titleformat{\section}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{13}\selectfont}
{\thesection}
{6pt}
{\MakeTextUppercase{#1}}
[]
\titleformat{\subsection}[block]{\bfseries\boldmath\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsection}
{6pt}
{#1}
[]
\titleformat{\subsubsection}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubsubsection}
{6pt}
{#1}
[]
\titleformat{\paragraph}[block]{\NormalBaseline\filright\fontsize{10.5}{10}\selectfont}
{\theparagraph}
{6pt}
{#1}
[]
\titleformat{\subparagraph}[block]{\NormalBaseline\filright\fontsize{10.5}{12}\selectfont}
{\thesubparagraph}
{6pt}
{#1}
[]

\titlespacing{\section}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subsubsection}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\paragraph}{0pt}{.5\baselineskip}{.5\baselineskip}  
\titlespacing{\subparagraph}{0pt}{.5\baselineskip}{.5\baselineskip}

\captionsetup[figure]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}
\captionsetup[table]{skip=1.4pt,font=bf,labelsep=colon,justification=raggedright,singlelinecheck=false}

\def\bibyear#1{#1}
%\def\bibjtitle#1{#1}   %%Publisher request
\def\bibauand{}
\setlength\bibsep{3pt}
\setlength\bibhang{8pt}

\makeatother
\date{}


\usepackage[flushleft]{threeparttablex}

\usepackage{float}

\begin{document}


\def\RunningAuthor{Manish Wani et al.}
\firstPage{7293}
\articleType{Original Article}
\receivedDate{23 Sep 2020}
\acceptedDate{23 Oct 2020}
\revisedDate{15 Oct 2020}
\journalVolume{2020, 11}
\journalIssue{4}
\journalDoi{ijrps.v11i4.3868}
\copyrightYear{2020}
\def\authorCount{6}
\def\affCount{2}

\def\journalTitle{International Journal of Research in Pharmaceutical Sciences}

\title{\textbf{Design and Evaluation of Flurbiprofen Micro-Emulsion Based Gel}}
\author{Manish~Wani\textsuperscript{*}\textsuperscript{1},  
            Akshay~Baheti\textsuperscript{1},  
            Satish~Polshettiwar\textsuperscript{1},  
            Tanaji~Nandgude\textsuperscript{2},  
            Aarti~Shastri\textsuperscript{1}, 
            Yogita~Ozarde\textsuperscript{1}~\\[5pt]{\textsuperscript{1}Department of Pharmaceutics, School of Pharmacy, Dr. Vishwanath Karad MIT World Peace University, Pune-411038, India}~\\{\textsuperscript{2}Department of Pharmaceutics, Dr. D Y Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune-411018, Maharashtra, India}}

\begin{abstract}
Flurbiprofen via oral route has many side effects. Many inflammatory infections occur locally and close to the body's surface, so topical application of flurbiprofen is advantageous. Still, intact skin acts as a barrier and hampers skin penetration of the drug. Present objective of this work was to reduce the adverse effect of flurbiprofen and increase its bioavailability by formulating Flurbiprofen microemulsion based gel, evaluating it for its Physico-chemical properties and then finally conducting its \textit{in-vitro} and animal studies to determine its efficiency. Arachis oil was selected as an oil phase as flurbiprofen showed maximum solubility in it. Microemulsion formulations (A1 to A9) were prepared by varying the qty of tween 80 (as a surfactant) and propylene glycol (as co-surfactant). Microemulsions which were found to give satisfactory results w.r.t microemulsion formation (F1 to F5) were converted to microemulsion gel using Carbopol 934 as gel base. The ability of different microemulsions to penetrate flurbiprofen through the skin was \textit{in-vitro evaluated}. All the formulations were evaluated for their quantity of drug present in the formulation, pH, Viscosity, Spreadability, in vitro diffusion study. Formula F4, which showed good Physico-chemical properties, was subjected to anti-inflammatory study. Results showed that pH, spreadability, viscosity and amount of active ingredient present in formulations were in an acceptable limit. The standard calibration curve for flurbiprofen depicts the linear association between concentration and absorbance. The formulation F4 has the highest \% release, 90.54\% also showed a higher \% inhibition of paw oedema after 4 hrs than marketed formulation.
\end{abstract}\def\keywordstitle{Keywords}

\begin{keywords}Flurbiprofen,\newline microemulsion gel,\newline tween 80,\newline propylene glycol,\newline paw oedema,\newline anti-inflammatory
\end{keywords}
\twocolumn[ \maketitle {\printKwdAbsBox}]
\makeatletter{\raggedright\textsuperscript{*}Corresponding Author\par Name:\ Manish~Wani~\\ Phone:\ +91- 976235652~\\  Email:\ manish.wani@mitwpu.edu.in
        \par}\vspace*{-11pt}\hrulefill\par{\fontsize{12}{14}\selectfont ISSN: 0975-7538}\par% 
        \textsc{DOI:}\ \href{https://doi.org/10.26452/\@journalDoi}{\textcolor{blue}{\underline{\smash{https://doi.org/10.26452/\@journalDoi}}}}\par%
        \vspace*{-11pt}\hrulefill\\{\fontsize{9.12}{10.12}\selectfont Production and Hosted by}\par{IJRPS |~\href{www.ijrps.com}{www.ijrps.com}}\par%
        \vspace*{-2pt}{\fontsize{9.12}{10.12}\selectfont\textcopyright\ \@copyrightYear\ $|$ All rights reserved.}\par%
        \vspace*{-11pt}\rule{\linewidth}{1.2pt}
        \makeatother
        
    
\section{Introduction}
Flurbiprofen belongs to the class of 2-aryl propionic acids group of compounds which have non-steroidal anti-inflammatory drugs activity \unskip~\citep{915072:20604443}. Flurbiprofen is weak acids, with a pKa of 3-5, it undergoes oxidative first past metabolism by enzymes in the hepatic system and excretion of its metabolites is through renal system and bile. On oral administration, flurbiprofen shows side effects like retching, puking, indigestion, ulceration of the intestine, gastric haemorrhage, and loose stool. As the duration of therapy increases, there is a risk that ulcers present in GIT may also get aggravated and also with an increase in doses there is a risk of increasing side effects \unskip~\citep{915072:20604441}. Topical application of flurbiprofen reduces these side effects. Topical routes also have advantages like they prevent the absorption and metabolism issues associated with oral administration; if the oral route is unsuitable, like in case of vomiting and diarrhoea, then the topical route can be a suitable replacement; moreover, topical routes are non-invasive thus minimizing risks and inconveniences associated with injectable; they can increase the bioavailability and drug effectiveness because hepatic first-pass is circumvented; the topical application has shown to have good patient compliance because of its simple application method; the action of the drug can be easily stopped by simple washing of the applied formulation from the surface of the skin, and they deliver the drug directly to the site of action \unskip~\citep{915072:20604444}. The main disadvantage of topical routes is the permeability of drug through barrier properties of intact skin \unskip~\citep{915072:20604445}. This can be overcome by developing microemulsion gel. 

Microemulsions are isotropic solutions which are made stable thermodynamically, by an effective surfactant or surfactant mixture. In this system, significant quantities of two immiscible liquids, often water and oil, are brought into a single-phase \unskip~\citep{915072:20604447}. 

A mixture of oil, water, and surfactant are converted into clear water-in-oil microemulsion. Water droplets are surfactant-stabilized in a continuous oil process. As per USP Gels are semi-solid structures made up of either small inorganic particles or large organic molecules that are enclosed and interpenetrated by liquid dispersion. A three-dimensional, unique structure of organic particles is an identity of gels. 

Gels are a two-phase system where big organic particles are dissolved in the continuous phase, while inorganic particles are dispersed in the continuous phase \unskip~\citep{915072:20604449}. Microemulsion gel is an amalgamation of microemulsion and gel. 

The aim and objectives of the present study were to formulate microemulsion gel of flurbiprofen which would be stable and have good permeation of flurbiprofen and would not cause irritation to skin.
    
\section{Materials and Methods}
Flurbiprofen was obtained from FDA India, Arachis Oil from McW Health Care Indore, Carbopol (934) from S. D. Fine Chemicals Mumbai and Tween 80, Propylene glycol from Lobachemie, Mumbai.

\textbf{Drug Identification Studies}

The drug under consideration, i.e. flurbiprofen, was checked for its purity by checking its melting point, FTIR and \ensuremath{\lambda } max. The melting point was determined by capillary method \unskip~\citep{915072:20604451}. The FTIR spectrum was compared with standard FTIR spectra of Flurbiprofen  \unskip~\citep{915072:20604451}. The UV spectrum was recorded over suitable wavelength, and \ensuremath{\lambda } max was determined by dissolving 10mg of the drug in 100ml of phosphate buffer (PB) pH 6.4, to obtain a concentration of 100\ensuremath{\mu}g/ml \unskip~\citep{915072:20604451}.


\begin{table*}[!htbp]
\caption{\boldmath {Formulation of Flurbiprofen Microemulsion} }
\label{tw-f69b326bfd6e}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.08239999999999998\linewidth-2\tabcolsep}p{\dimexpr.13680000000000001\linewidth-2\tabcolsep}p{\dimexpr.0704\linewidth-2\tabcolsep}p{\dimexpr.0825\linewidth-2\tabcolsep}p{\dimexpr.0779\linewidth-2\tabcolsep}p{\dimexpr.09\linewidth-2\tabcolsep}p{\dimexpr.09\linewidth-2\tabcolsep}p{\dimexpr.09\linewidth-2\tabcolsep}p{\dimexpr.09\linewidth-2\tabcolsep}p{\dimexpr.09\linewidth-2\tabcolsep}p{\dimexpr.10\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}{\multirow{2}{*}{Sr No}} & {\multirow{2}{*}{Material }} & \multicolumn{9}{p{\dimexpr(.7808\linewidth-2\tabcolsep)}}{\cAlignHack Trail Batches }\\
\rowcolor{kwdboxcolor} &  & A1  & A2  & A3  & A4  & A5  & A6 & A7 & A8 & A9\\
\tblmidrule 
1  &
  Flurbiprofen  &
  3g  &
  3g  &
  3g  &
  3g  &
  3g  &
  3g &
  3g &
  3g &
  3g\\
2  &
  Arachis oil  &
  8g  &
  8g  &
  8g  &
  8g  &
  8g  &
  8g &
  8g &
  8g &
  8g\\
3  &
  Tween 80  &
  10 &
  10 &
  10 &
  12 &
  12 &
  12 &
  14g  &
  14g  &
  14g \\
4  &
  Propylene Glycol  &
  6g  &
  7g  &
  8g  &
  6g  &
  7g  &
  8g  &
  6g  &
  7g  &
  8g \\
5  &
  Distilled Water  &
  qs &
  qs &
  qs &
  qs &
  qs &
  qs &
  qs &
  qs &
  qs\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Formulation of Flurbiprofen Microemulsion gel} }
\label{tw-d070cad21732}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.09305714285714284\linewidth-2\tabcolsep}p{\dimexpr.19265714285714285\linewidth-2\tabcolsep}p{\dimexpr.14285714285714285\linewidth-2\tabcolsep}p{\dimexpr.14285714285714285\linewidth-2\tabcolsep}p{\dimexpr.14285714285714285\linewidth-2\tabcolsep}p{\dimexpr.14285714285714285\linewidth-2\tabcolsep}p{\dimexpr.14285714285714285\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}{\multirow{2}{*}{Sr No  }} & {\multirow{2}{*}{Material }} & \multicolumn{5}{p{\dimexpr(.7142857142857142\linewidth-2\tabcolsep)}}{\cAlignHack Final Batches}\\
\rowcolor{kwdboxcolor} &  & F1  & F2  & F3  & F4  & F5 \\
\tblmidrule 
1 &
  Flurbiprofen &
  3g &
  3g &
  3g &
  3g &
  3g\\
2 &
  Arachis oil &
  8g &
  8g &
  8g &
  8g &
  8g\\
3 &
  Tween 80 &
  10g &
  12g &
  14g &
  14g &
  14g\\
4 &
  Propylene Glycol &
  8g &
  8g &
  6g &
  7g &
  8g\\
5 &
  Distilled Water &
  qs &
  qs &
  qs &
  qs &
  qs\\
6 &
  Carbopol 934 &
  2g &
  2.5g &
  3g &
  3.5g &
  4g\\
7. &
  Triethanolamine &
  1.5 ml &
  1.5 ml &
  1.5 ml &
  1.5 ml &
  1.5 ml\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Group specifications for In vivo Anti-inflammatory study} }
\label{tw-9791168c880d}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.2346\linewidth-2\tabcolsep}p{\dimexpr.36730000000000004\linewidth-2\tabcolsep}p{\dimexpr.3981\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}Sr. No. & Formulation & Group\\
\tblmidrule 

  ~\newline 1.~1. ~\newline  &
  Control 1 &
  I\\

  ~\newline 1.~2. ~\newline  &
  Formulation F4- A &
  II\\

  ~\newline 1.~3. ~\newline  &
  Control 2 &
  III\\

  ~\newline 1.~4. ~\newline  &
  Formulation F4-B &
  IV\\

  ~\newline 1.~5. ~\newline  &
  Marketed gel &
  V\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Flurbiprofen solubility in various oils} }
\label{tw-976802ee3627}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.471\linewidth-2\tabcolsep}p{\dimexpr.529\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}Oil & Solubility mg/ml\\
\tblmidrule 
Arachis oil &
  20.63\\
Corn oil &
  3.25\\
Sesame oil &
  3.42\\
Olive oil &
  4.31\\
Mineral oil &
  0.57\\
IPM &
  5.73\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {\% of the active ingredient in Microemulsion Gel } }
\label{tw-03c8b8dccfba}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.0851\linewidth-2\tabcolsep}p{\dimexpr.14410000000000002\linewidth-2\tabcolsep}p{\dimexpr.0879\linewidth-2\tabcolsep}p{\dimexpr.0731\linewidth-2\tabcolsep}p{\dimexpr.0686\linewidth-2\tabcolsep}p{\dimexpr.11090000000000003\linewidth-2\tabcolsep}p{\dimexpr.08970000000000002\linewidth-2\tabcolsep}p{\dimexpr.13120000000000001\linewidth-2\tabcolsep}p{\dimexpr.20939999999999998\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}{\multirow{2}{*}{Sr. No. }} & {\multirow{2}{*}{Formulations }} & \multicolumn{4}{p{\dimexpr(.3405\linewidth-2\tabcolsep)}}{\cAlignHack \% of the active ingredient } & {\multirow{2}{*}{pH* }} & Viscosity* & Spreadability*\\
\rowcolor{kwdboxcolor} &  & 1 & 2 & 3 & Mean \mbox{}\protect\newline \ensuremath{\pm} S. D. &  & (centipoise) &
  (Mean \ensuremath{\pm} SD)\\
\tblmidrule 
1 &
  F1 &
  95.54 &
  96.74 &
  96.74 &
  96.34 &
  7.64 &
  92400 &
  15.882 \ensuremath{\pm} 0.291\\
2 &
  F2 &
  97.51 &
  98.54 &
  96.24 &
  97.43 &
  7.35 &
  107100 &
  17.928 \ensuremath{\pm} 0.300\\
3 &
  F3 &
  100.23 &
  97.45 &
  91.58 &
  96.42 &
  7.47 &
  107600 &
  18.382 \ensuremath{\pm} 0.191\\
4 &
  F4 &
  99.47 &
  99.85 &
  98.49 &
  99.27 &
  7.37 &
  108100 &
  21.962 \ensuremath{\pm} 0.187\\
5 &
  F5 &
  94.87 &
  94.58 &
  96.57 &
  95.34 &
  7.85 &
  108300 &
  27.252 \ensuremath{\pm} 0.214\\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{*Mean of three determinations (n=3)}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {In Vitro Diffusion Study of Microemulsion Gel} }
\label{tw-e1e056fce606}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.09370000000000001\linewidth-2\tabcolsep}p{\dimexpr.1863\linewidth-2\tabcolsep}p{\dimexpr.14\linewidth-2\tabcolsep}p{\dimexpr.14\linewidth-2\tabcolsep}p{\dimexpr.14\linewidth-2\tabcolsep}p{\dimexpr.14\linewidth-2\tabcolsep}p{\dimexpr.16\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}Sr. No.  & Time  & Avg. \%R  \mbox{}\protect\newline F1  & Avg. \%R  \mbox{}\protect\newline F2  & Avg. \%R  \mbox{}\protect\newline F3  & Avg. \%R  \mbox{}\protect\newline F4  & Avg. \%R  \mbox{}\protect\newline F5 \\
\tblmidrule 
1  &
  0 &
  0 &
  0 &
  0 &
  0 &
  0\\
2  &
  15 &
  1.007 &
  1.742 &
  1.742 &
  1.007 &
  2.476\\
3  &
  30 &
  9.122 &
  6.209 &
  4.005 &
  4.715 &
  6.234\\
4  &
  60 &
  21.188 &
  16.704 &
  10.018 &
  13.69 &
  9.384\\
5  &
  120 &
  35.128 &
  31.227 &
  28.72 &
  32.519 &
  23.654\\
6  &
  180 &
  54.666 &
  46.231 &
  39.975 &
  47.574 &
  32.528\\
7  &
  240 &
  68.226 &
  60.247 &
  53.789 &
  55.764 &
  52.699\\
8  &
  300 &
  80.722 &
  73.225 &
  66.564 &
  65.652 &
  61.042\\
9  &
  360 &
  81.042 &
  75.255 &
  81.188 &
  79.491 &
  71.082\\
10  &
  420 &
  -- &
  -- &
  -- &
  83.051 &
  --\\
11  &
  480 &
  -- &
  -- &
  -- &
  90.544 &
  --\\
\multicolumn{2}{p{\dimexpr(.28\linewidth-2\tabcolsep)}}{t50} &
  164min &
  199min &
  215min &
  223min &
  228min\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Percent oedema inhibition shown by formulation F4} }
\label{tw-4e67ec2ef052}
\centering 
\begin{threeparttable}

\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{LLLLLL}
\tbltoprule \rowcolor{kwdboxcolor}{\multirow{2}{*}{Sr. No. }} & {\multirow{2}{*}{Formulation }} & \multicolumn{4}{p{\dimexpr(\mcWidth{3}+\mcWidth{4}+\mcWidth{5}+\mcWidth{6})}}{Mean paw oedema volume after (\ensuremath{\pm} S. E. M.) }\\
\rowcolor{kwdboxcolor} &  & 1hr.  & 2hr.  & 3hr.  & 4hr. \\
\tblmidrule 
1.  &
  Control  &
  0.258 \ensuremath{\pm} 0.019  &
  0.329 \ensuremath{\pm} 0.0025  &
  0.296 \ensuremath{\pm} 0.020  &
  0.301 \ensuremath{\pm} 0.052 \\
2.  &
  F4  &
  0.163 \ensuremath{\pm} 0.0046**  &
  0.114 \ensuremath{\pm} 0.0028**  &
  0.097 \ensuremath{\pm} 0.0054**  &
  0.142 \ensuremath{\pm} 0.0039** \\
3.  &
  Marketed  &
  0.179 \ensuremath{\pm} 0.0038**  &
  0.184 \ensuremath{\pm} 0.0026**  &
  0.097 \ensuremath{\pm} 0.0014**  &
  0.946 \ensuremath{\pm} 0.0021** \\
\tblbottomrule 
\end{tabulary}\par 
\begin{tablenotes}\footnotesize 
    
\item{** P \ensuremath{\leq } 0.01}
\end{tablenotes}
\end{threeparttable}

\end{table*}

\begin{table*}[!htbp]
\caption{\boldmath {Stability Study of Formulation F4\ensuremath{_{}}} }
\label{tw-e169784db723}
\def\arraystretch{1.1}
\ignorespaces 
\centering 
\begin{tabulary}{\linewidth}{p{\dimexpr.08919999999999998\linewidth-2\tabcolsep}p{\dimexpr.1108\linewidth-2\tabcolsep}p{\dimexpr.10\linewidth-2\tabcolsep}p{\dimexpr.10\linewidth-2\tabcolsep}p{\dimexpr.10\linewidth-2\tabcolsep}p{\dimexpr.10\linewidth-2\tabcolsep}p{\dimexpr.10\linewidth-2\tabcolsep}p{\dimexpr.11\linewidth-2\tabcolsep}p{\dimexpr.09\linewidth-2\tabcolsep}p{\dimexpr.10\linewidth-2\tabcolsep}}
\tbltoprule \rowcolor{kwdboxcolor}\multicolumn{2}{p{\dimexpr(.20\linewidth-2\tabcolsep)}}{\multirow{3}{\linewidth}{Formulation  \mbox{}\protect\newline F4 }} & \multicolumn{8}{p{\dimexpr(.80\linewidth-2\tabcolsep)}}{Storage condition }\\
\rowcolor{kwdboxcolor} &  & \multicolumn{4}{p{\dimexpr(.40\linewidth-2\tabcolsep)}}{25\ensuremath{^\circ}  C \ensuremath{\pm} 2\ensuremath{^\circ}  C at 75 \ensuremath{\pm} 5 \% RH} & \multicolumn{4}{p{\dimexpr(.40\linewidth-2\tabcolsep)}}{40\ensuremath{^\circ}  C \ensuremath{\pm} 2\ensuremath{^\circ}  C at 75 \ensuremath{\pm} 5 \% RH}\\
\rowcolor{kwdboxcolor} &  & \multicolumn{4}{p{\dimexpr(.40\linewidth-2\tabcolsep)}}{Months} & \multicolumn{4}{p{\dimexpr(.40\linewidth-2\tabcolsep)}}{Months}\\
\rowcolor{kwdboxcolor}Sr. No. & Parameter  & 0 & 1 & 2 & 3 & 0  & 1  & 2  & 3 \\
\tblmidrule 
1.  &
  Drug content (\%)  &
  99.7 \ensuremath{\pm} 0.232 &
  98.98 \ensuremath{\pm} 0.548 &
  98.66 \ensuremath{\pm} 0.654 &
  98.25 \ensuremath{\pm} 0.145 &
  99.59 \ensuremath{\pm} 0.148 &
  98.23 \ensuremath{\pm} 0.784 &
  97.82 \ensuremath{\pm} 0.481 &
  97.99\ensuremath{\pm} 0.412\\
2.  &
  Viscosity (Poise)  &
  102458 &
  124578 &
  102457 &
  104578 &
  103568 &
  110458 &
  102478 &
  104578\\
3.  &
  pH  &
  9.21 &
  9.24 &
  9.45 &
  9.24 &
  9.54 &
  8.94 &
  9.14 &
  8.91\\
4.  &
  Spreadability (gcm/sec)  &
  27.45\ensuremath{\pm} 0.145 &
  27.56\ensuremath{\pm} 0.247 &
  26.97\ensuremath{\pm} 0.548 &
  27.12\ensuremath{\pm} 0.462 &
  28.01\ensuremath{\pm} 0.476 &
  27.94\ensuremath{\pm} 0.157 &
  28.07\ensuremath{\pm} 0.459 &
  27.66\ensuremath{\pm} 0.457\\
5.  &
  Diffusion study  &
  90.14\ensuremath{\pm} 0.478 &
  90.47\ensuremath{\pm} 0.014 &
  89.76\ensuremath{\pm} 0.125 &
  89.47\ensuremath{\pm} 0.478 &
  90.48\ensuremath{\pm} 0.125 &
  90.01\ensuremath{\pm} 0.784 &
  90.00\ensuremath{\pm} 0.412 &
  89.75\ensuremath{\pm} 0.047\\
\tblbottomrule 
\end{tabulary}\par 
\end{table*}
\textbf{Preformulation Studies}

\textbf{Checking solubility of the drug in oils\ensuremath{^{}}}

To determine oil that can be used to solubilize active ingredient flurbiprofen so that the same can be dispersed phase in the microemulsion, flurbiprofen was mixed in various oils, and its solubility was measured \unskip~\citep{915072:20604450}. Oils used in this study were cottonseed oil, Arachis oil, corn oil, sesame oil, olive oil, mineral oil, IPM. For 5 ml of each oil, an excess amount of flurbiprofen was added and shaken for 72 h at 30\ensuremath{^\circ}C. A cellophane membrane filter was used to filter the suspension, and the drug concentration in the filtrate was measured using the UV process. The flurbiprofen oil mixture was filtered through a cellophane membrane filter, and the drug concentration in the filtrate was determined using the UV method \unskip~\citep{915072:20604450}.

\textbf{Compatibility studies}

FT-IR spectrum of the drug mixed with excipients was compared with Individual IR spectra of the Flurbiprofen \unskip~\citep{915072:20604452}  taken using KBr pellet, between 4000cm\ensuremath{^{-1}} to 500cm\ensuremath{^{-1}} range.

\textbf{Calibration Curve}

Standard curve of the Flurbiprofen  in PB pH 6.4 \unskip~\citep{915072:20604453} was plotted by recording the absorbance of solutions at different concentrations (4-20\ensuremath{\mu }g/ml).

\textbf{Formulation and Development of Flurbiprofen Microemulsion Gel}

\textbf{Formulation of Flurbiprofen Microemulsion}

Surfactant, Co-surfactant mixture with different ratios were prepared (Table~\ref{tw-f69b326bfd6e}). Flurbiprofen was dissolved in Arachis oil. In the next step, the surfactant/ co-surfactant mixture was added to Flurbiprofen in Arachis oil. Oily mixtures were subjected to gentle agitation with the help of magnetic stirrer and drop by drop water was added to each of them. Beginning of phase inversion area is noted when the clear mixture became turbid at a certain point. O/W microemulsion formation takes place when the turbid mixture turns clear. 

Finally, we can say O/W microemulsion has terminated when the system becomes turbid once again with the continuous addition of water \unskip~\citep{915072:20604455}. 

The experiment was repeated at different quantities of S/CoS keeping constant ratio \unskip~\citep{915072:20604455}. Suitable oil, surfactant and co-surfactant quantities were selected (Formulation F1 to F5) for further studies, based on the results obtained from the above experiment. 

\textbf{Converting of Flurbiprofen Microemulsion to Flurbiprofen Microemulsion Gel}

To the formulated microemulsions, carbopol 934 \unskip~\citep{915072:20604454} was added in incremental quantity (Table~\ref{tw-d070cad21732}) and dispersed. To this mixture, slowly, triethanolamine was added \unskip~\citep{915072:20604454}. This gel was used for further studies 

\textbf{Evaluation of Microemulsion Gel}

\textbf{Psycho rheological analysis}

The prepared gels were examined with naked eye against a white and black background for transparency, the appearance of any lumps \unskip~\citep{915072:20604457} and any unexpected changes in viscosity. The preparations were applied on the skin to measure the sensation, and the sensations were documented clinically.

\textbf{Drug Content}

 0.5g of the formulation was drawn in a volumetric flask of 50 ml capacity, and it was diluted with PB and drug was dissolve in phosphate buffer by continuous shaking \unskip~\citep{915072:20604457}. This solution was passed through Whatman filter paper no. 42. From the filtrate obtained 1 ml of was withdrawn and diluted to 10 ml with PB. The standard curve was used to spectrophotometric calculation of the quantity of the drug present \unskip~\citep{915072:20604457} infiltrate.

\textbf{pH determination}

The pH of prepared microemulsion gels was decided using pH meter \unskip~\citep{915072:20604458}. 

\textbf{Viscosity}

Brookfield viscometer was used to find out viscosity of prepared gels. For this, in the cylindrical tube, 10g of microemulsion gel was loaded, and the dial reading was recorded at 60 rpm \unskip~\citep{915072:20604458}. Dial readings were multiplied with factor given in the catalogue. The results obtained indicated the viscosity in cps.

\textbf{Spreadability}

For determining spreadability of preparations, the apparatus was fabricated in the laboratory as suggested by Multimer et al. 2.5 g of microemulsion gel sample was placed between movable and fixed glass. Weight of 1000g \unskip~\citep{915072:20604458}  was kept on movable slides for 5 min so that the uniform distribution of gel takes place between both glass sides. 60g weight was kept on the pan which was attached to a movable glass slide with thread. The time required for the movable glass slide to separate and to travel distance l in seconds was observed. Spreadability was calculated using the formula \unskip~\citep{915072:20604458}.

S = m.l / t. Where, S - Spreadability in g.cm / sec, t - Time measured in sec, l {\textendash} distance traveled by, m - Weight inside pan.

\textit{\textbf{In Vitro}} \textbf{ Diffusion Study}

In vitro diffusion experiment was done to evaluate the process of release of drugs from formulations. Prepared gels were subjected to in vitro diffusion analysis using Franz diffusion cell and cellophane membrane \unskip~\citep{915072:20604457}. PB (pH 7.4) was filled in the receiving compartment \unskip~\citep{915072:20604457}. Sink conditions were maintained with the help of PB throughout the analysis. The entire assembly was held at 37 \ensuremath{\pm} 1\ensuremath{^{0}}C, and the receptor solution was mixed at 600 rpm during the procedure with a magnetic stirrer. Care was taken to keep air bubbles from being caught under the membrane. Aliquots (1 ml) were extracted at fixed one h intervals for a period of 8h, and an equal volume of fresh medium was replaced \unskip~\citep{915072:20604457}. Samples were correctly diluted with PB medium and spectrophotometrically analyzed for flurbiprofen content at 247 nm. At each time, the total qty of flurbiprofen diffused per unit area of the membrane was analyzed.

\textit{\textbf{In vivo }} \textbf{Anti-inflammatory study\textit{}}

Using 30 albino rats of both sex, and \textit{in-vivo} anti-inflammatory analysis was carried out \unskip~\citep{915072:20604460} (approved by the Institutional Animal Ethical Committee, MAEERS MIP Pune). The weight of theses rats was in the range of 100-150g. They were divided into five groups. Acute inflammation was produced in all groups, by injecting 0.1 ml (sub-planter) in left hind paw of the rats freshly prepared carrageenan 1 \% suspension in normal saline \unskip~\citep{915072:20604460}. 0.25g of medicated gel or base was topically dabbed on the paw of each rat of respective group one hour before and after the carrageenan challenge. 1, 2, 3 and 4 hours after injection of carrageenan paw oedema volume was measured using plethysmometer\ensuremath{^{}}\unskip~\citep{915072:20604460}. The average volume of the groups was determined and compared with control. The per cent inhibition of oedema was calculated by using the following formula \unskip~\citep{915072:20604460}. 

\% Edema inhibition = (1- Vt / Vc) 100

Where, Vt - Mean oedema volume of test and Vc - Mean oedema volume of control

Statistical significance was calculated by using the student's unpaired `t' test. Group specifications are shown in (Table~\ref{tw-9791168c880d}) .

\textbf{Stability Study}

\textbf{Freeze-thaw and thermal cycling test}

In a cyclic pattern, the chosen microemulsion gel were subjected to varying temperature conditions that mimic the condition that is likely to occur during its use or in the delivery process. One cycle was completed when the chosen formulations were exposed to cooling temperatures (2-8\ensuremath{^\circ}C) for two days, followed by 40\ensuremath{^\circ}C for next two days \unskip~\citep{915072:20604461}. Such three freeze-thaw cycles were accomplished in twelve days. During this period, any significant changes in microemulsion gel were observed.

Once no significant change was observed, these microemulsion gel were then subjected to the following condition of temperature and relative humidity during stability studies. 

 25\ensuremath{^\circ}C \ensuremath{\pm} 2\ensuremath{^\circ}C at 75 \ensuremath{\pm} 5\% RH and 40\ensuremath{^\circ}C \ensuremath{\pm} 2\ensuremath{^\circ}C at 75 \ensuremath{\pm} 5\% RH  

Formulations were evaluated for various parameters after every month for three months. The parameters \unskip~\citep{915072:20604461}  of the microemulsion gel studied were the amount of active ingredient, rheology, pH change and In vitro diffusion study. 
    
\section{Results and Discussion}
\textbf{Drug Identification Studies}

The melting point of the drug sample was found in the range of 161-163\ensuremath{^\circ}C, as reported in the literature for flurbiprofen. FTIR of drug sample (Figure~\ref{f-c5a8fedaf4fc}) was found to match with standard FTIR of Flurbiprofen. Standard functional group frequencies matched with observed frequencies of flurbiprofen. The recorded UV spectra of drug sample showed the absorbance maxima (\ensuremath{\lambda }max) at 247nm confirming the purity of Flurbiprofen (Figure~\ref{f-6b2a6a6f48b6}).


\bgroup
\fixFloatSize{images/dd1a22ad-07ab-4283-b51d-e4449d346272-upicture1.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/dd1a22ad-07ab-4283-b51d-e4449d346272-upicture1.png}{\includegraphics{images/dd1a22ad-07ab-4283-b51d-e4449d346272-upicture1.png}}{}
\makeatother 
\caption{\boldmath {FT-IR Spectra of Flurbiprofen}}
\label{f-c5a8fedaf4fc}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/2c630600-ec65-4904-bd3f-9cb62e0e7de7-upicture2.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/2c630600-ec65-4904-bd3f-9cb62e0e7de7-upicture2.png}{\includegraphics{images/2c630600-ec65-4904-bd3f-9cb62e0e7de7-upicture2.png}}{}
\makeatother 
\caption{\boldmath {UV Spectra of Flurbiprofen}}
\label{f-6b2a6a6f48b6}
\end{figure}
\egroup
\textbf{Formulation and Development of Flurbiprofen Microemulsion Gel}

The solubility of flurbiprofen in various oils at 35\ensuremath{^\circ}C observed were tabulated in (Table~\ref{tw-976802ee3627}). Flurbiprofen was found to have maximum solubility in Arachis oil, and hence that was selected as an excipient for formulating microemulsion. Combination IR spectra of Flurbiprofen with Arachis oil (Figure~\ref{f-6883b2d66493}) and Flurbiprofen with Carbopol (Figure~\ref{f-8df3ba173a61}) were obtained. When compared with individual IR spectra of flurbiprofen, no peak distortions were found. Thus it can be concluded that flurbiprofen is compatible with Arachis oil Carbopol. Absorbance recorded at different concentrations (1-5\ensuremath{\mu }g/ml) showed that Beer and Lambert's law was followed, the coefficient of correlation was 0.995 and equation of regressed obtained was Y = 0.0731X. Microemulsions containing flurbiprofen was successfully formulated, taking the optimum quantity of Arachis oil, Tween 80 - Propylene Glycol as a surfactant - co-surfactant combination. This formulated flurbiprofen microemulsion was then successfully converted to gel using carbopol as a gelling agent. 


\bgroup
\fixFloatSize{images/101501ca-03a4-4939-8f9d-0db6f4e0ff29-upicture3.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/101501ca-03a4-4939-8f9d-0db6f4e0ff29-upicture3.png}{\includegraphics{images/101501ca-03a4-4939-8f9d-0db6f4e0ff29-upicture3.png}}{}
\makeatother 
\caption{\boldmath {Combination Flurbiprofen- Arachis oil FTIR Spectra}}
\label{f-6883b2d66493}
\end{figure}
\egroup

\bgroup
\fixFloatSize{images/1c05008c-7d59-4f6c-91ea-45d449f31b1f-upicture4.png}
\begin{figure}[!htbp]
\centering \makeatletter\IfFileExists{images/1c05008c-7d59-4f6c-91ea-45d449f31b1f-upicture4.png}{\includegraphics{images/1c05008c-7d59-4f6c-91ea-45d449f31b1f-upicture4.png}}{}
\makeatother 
\caption{\boldmath {Combination Flurbiprofen- Carbopol FTIR Spectra}}
\label{f-8df3ba173a61}
\end{figure}
\egroup
\textbf{Evaluation of Microemulsion Gel}

Flurbiprofen gel formulations were found to be transparent and possessed smooth texture; this was because carbopol quantity was kept below 4.5g. The pH of all gel formulation was found in between 7.35 to 7.85, the high values of pH are attributed to the addition of tri ethanol amine which is used as pH modulator to bring about sol to gel conversion of gelling agent carbopol. Viscosity is an essential parameter in semi-solid preparations low viscosity would cause draining of the preparation from the skin. In contrast, high viscosity would result in poor spreadability, poor extrudability and would affect drug release too. 

The viscosity of the formulated gel was found to be optimum in the range of 92400cps to 108300. Drug content study indicated that the Flurbiprofen microemulsion was uniform during gel formation and the drug content within permissible limits. Spreadability is vital from the view of patient compliance as easily spreadable gel gives a good feel to the patient. It also helps in the uniform application of gel on the skin. 

The spreadability of the formulated gel decreased as the concentration of gelling agent increased. Amount of active ingredient present in the gel was 95.34\% (F5) to 99.27\% (F4) showing that the drug is evenly distributed in the formulation. The results of pH, Viscosity and Spreadability are tabulated in Table~\ref{tw-03c8b8dccfba}. 

\textit{\textbf{In Vitro}} \textbf{ Diffusion Study}

The drug release data obtained are tabulated in Table~\ref{tw-e1e056fce606}. It was observed that \% release of drug was 81.04\%, 75.25\%, 81.18\%, 90.54\% and 71.08\% in formulations from F1 to F5 respectively. 

F4 formulation show 90.54\% release of the active ingredient after twelve hours. 

In vitro release, results showed that sustained release was shown by the F4 formulation and could keep the release medicament for an extended amount of time (12 hours). It was therefore further used for animal research and trials of stability.

\textit{\textbf{In vivo}} \textbf{ Anti-inflammatory study}

The results of the effect of formulation F4 of Flurbiprofen microemulsion gel on carrageenan-induced oedema are shown in Table~\ref{tw-4e67ec2ef052}. Formulation F4 of Flurbiprofen microemulsion gel demonstrated noteworthy anti-inflammatory activity when compared with control and marketed. 

\textbf{Stability Study}

No significant change was found in formulation F4 with regards to \% of the amount of active ingredient, Viscosity, pH, Spreadability \& Diffusion study after one month, two months and three months of stability studies (Table~\ref{tw-e169784db723}).
    
\section{Conclusions}
The received sample of flurbiprofen was checked for its characterization and was found to be of good quality. The purity of excipients was verified, and they were found to be compatible with the drug. Different topical formulations were developed successfully and were evaluated for various quality control test, which will determine its safety efficacy and stability. It was observed that all formulations had a good texture which was evident from the fact that no lump was present in a smooth microemulsion gel. It was found that the pH, spreadability, viscosity and qty of active ingredient were in the correct range. Standard calibration curves for flurbiprofen were prepared. The line equation was y = 0.0731x (R\ensuremath{^{2}} = 0.995). Correlation coefficient (R\ensuremath{^{2}}) values indicate the linear association between absorbance and concentration. \% release of Formulation F4 was highest at 90.54\%, and hence the same was used for further studies. The formulation F4 showed a higher \% inhibition of paw oedema after 4 hrs than the marketed formulation\textbf{.} Finally, formulation F4 was found to be stable and doesn't show precipitation, aggregation, separation of phases and significant rheological changes in freeze-thaw and thermal cycling test. From the studies, we can conclude that developed Flurbiprofen microemulsion gel is having enhanced anti-inflammatory activity than marketed formulations.

\textbf{Acknowledgement}

We are very much thankful to BCUD (now BOD), SPPU, Pune for funding this work and we also thank the management of Dr Vishwanath Karad, MIT World Peace University, School of Pharmacy, MIT Campus, Kothrud, Pune, 411038 for providing necessary help in carrying out the study in their laboratories.

\textbf{Conflict of Interest}

The researchers mention no conflicts of interest. The composition and writing of the document are the sole responsibility of the writer.

\textbf{Funding Support}

We have received funds from BCUD (now BOD), Savitribai Phule Pune University, Pune (Reference No. BCUD/OSD/84) for this work.
    

\bibliographystyle{pharmascope_apa-custom}

\bibliography{\jobname}
\end{document}
